1092364-38-9 | 1-[4-[[4-[(3,4-Dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-2-propen-1-one

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$9.00	$6.00
5mg	98%	in stock	$16.00	$11.00
10mg	98%	in stock	$28.00	$19.00
100mg	98%	in stock	$136.00	$95.00
250mg	98%	in stock	$232.00	$162.00
1g	98%	in stock	$558.00	$391.00
5g	98%	in stock	$1,879.00	$1,316.00

Description

• Catalog Number: AB52199
• Chemical Name: 1-[4-[[4-[(3,4-Dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-2-propen-1-one
• CAS Number: 1092364-38-9
• Molecular Formula: C23H21Cl2FN4O3
• Molecular Weight: 491.3422
• MDL Number: MFCD28044290
• SMILES: C=CC(=O)N1CCC(CC1)Oc1cc2c(ncnc2cc1OC)Nc1ccc(c(c1F)Cl)Cl

Computed Properties

• Complexity: 684
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 33
• Hydrogen Bond Acceptor Count: 7
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 6
• XLogP3: 5.4

Upstream Synthesis Route

The compound $name$ is often utilized in chemical synthesis as a key intermediate in the production of various pharmaceutical agents. Its unique structure, consisting of a substituted quinazoline core connected to a piperidine moiety and a propenone functional group, enables it to participate in diverse reactions leading to the formation of complex molecules. In particular, $name$ can serve as a building block for designing novel drug candidates targeting specific biological pathways. Its strategic placement within a synthetic route allows for the introduction of additional functionalities or structural modifications, ultimately influencing the compound's pharmacological properties. By incorporating $name$ into a synthesis, chemists can access a valuable tool for the development of potential therapeutic agents with enhanced efficacy and selectivity.

Literature

• Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.

  International journal of cancer 20120515

• Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.

  Cancer letters 20110328